Sydnexis is decreasing myopic progression in children.

See How

Sydnexis is decreasing myopic progression in children.

See How

A novel, stable, & comfortable topical eyedrop used once daily at bedtime.

See How
The STAR Study Logo

Treating Myopia with the STAR Study

A Phase 3 study to treat the progression of myopia in children.
Learn More

Are you a patient?

Learn more about Myopia & how to treat it.
Click Here

Latest News

Sydnexis Completes Enrollment in Phase 3 Clinical Trial
See more at ClinicalTrials.gov.
Read More
May 15, 2021
Sydnexis Secures $45 Million Series B
Financing Led by Visionary Ventures and Bluestem Capital
Read More
August 10, 2021
Previous News